Clinical responses have been observed after the administration of omalizumab, a humanized anti-IgE antibody, to patients with food allergy, which correlated with the suppression of degranulation of basophils.1, 2 These results indicate that actions aimed to blocking or modulating the IgE/FcεRI axis represent a promising strategy for the treatment of allergy and anaphylaxis. The gene discussed is IGHE; the disease is anaphylaxis.